Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309650 | 1.00 | REN (0.31) | RENCTSSNAMPTMMP1MMP13 | |
| SCHEMBL1073190 | 0.99 | REN (0.33) | RENCTSSNAMPTMMP1MMP13 | |
| SCHEMBL12963756 | 0.95 | REN (0.34) | RENCTSS | |
| SCHEMBL1068683 | 0.93 | F2 (0.34) | CTSSNAMPTMMP1MMP13LSS | |
| SCHEMBL20292517 | 0.91 | ALDH1A1 (0.33) | RENCTSS | |
| SCHEMBL1072629 | 0.91 | ALDH1A1 (0.33) | RENCTSS | |
| SCHEMBL1072401 | 0.87 | MMP13 (0.35) | MMP1MMP13 | |
| SCHEMBL1071682 | 0.87 | MMP13 (0.35) | MMP1MMP13 | |
| SCHEMBL1071128 | 0.87 | REN (0.33) | RENCTSSMMP1MMP13 | |
| SCHEMBL1072256 | 0.87 | REN (0.33) | RENCTSSMMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-2268285-B1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
| US-8591878-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| WO-2008057209-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | REN 3288/4885CTSS 65/4885NAMPT 1874/4885 |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | REN 3288/4885CTSS 65/4885NAMPT 1874/4885 |
| US-20110002884-A1 | THERAPEUTIC COMPOUNDS | RRP1B, ZC3HAV1, RNASE1 | REN 558/4885CTSS 63/4885NAMPT 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.